Meningococcal serogroup B vaccines: Estimating breadth of coverage

References

• Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001; 15(1):155-169; PMID:11301813; http://dx.doi.org/10.1016/S0891-5520(05)70273-7
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-28; PMID:23515099
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: technical & clinical information. Available at: http://www.cdc.gov/meningococcal/clinical-info.html. Accessed July 13, 2015.
   Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012; 30 Suppl 2: B3-9; PMID:22607896; http://dx.doi.org/10.1016/j.vaccine.2011.12.062
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013; 19:566-573; PMID:23628376; http://dx.doi.org/10.3201/eid1904.111799
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network Neisseria meningitidis, 2013-provisional. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mening13.pdf. Accessed September 13, 2016.
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2012. Available at: http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf. Accessed October 22, 2015.
   Google Scholar
• Li YA, Tsang R, Desai S, Dehhan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Communicable Dis Rep 2014; 40:160-169.
   Google Scholar
• Dey A, Knox S, Wang H, Beard FH, McIntyre PB. Summary of national surveillance data on vaccine preventable diseases in Australia, 2008-2011. Commun Dis Intell Q Rep 2016; 40:S1-S70; PMID:27087017
   PubMedGoogle Scholar
• Lopez L, Sherwood J. The epidemiology of meningococcal disease in New Zealand in 2013. Institute of Enviornmental Science and Research (ESR). Available at: https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2013/2013AnnualRpt.pdf. Accessed October 1, 2015.
   Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1171-1176; http://dx.doi.org/10.15585/mmwr.mm6441a3
   PubMed Web of Science ®Google Scholar
• O'Connor L, Ward M, Bennett D, Mulhall R, O'Lorcain P, Cunney R, McDermott R, Neville E, Heslin J, FitzGerald R, et al. A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013. Euro Surveill 2015; 20; pii:21139; PMID:26062560
   PubMedGoogle Scholar
• Tzanakaki G, Kesanopoulos K, Yazdankhah SP, Levidiotou S, Kremastinou J, Caugant DA. Conventional and molecular investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, Greece. Clin Microbiol Infect 2006; 12:1024-1026; PMID:16961641; http://dx.doi.org/10.1111/j.1469-0691.2006.01521.x
   PubMed Web of Science ®Google Scholar
• Stewart A, Coetzee N, Knapper E, Rajanaidu S, Iqbal Z, Duggal H. Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England. Perspect Public Health 2013; 133:104-109; PMID:23467531; http://dx.doi.org/10.1177/1757913912439928
   PubMed Web of Science ®Google Scholar
• Chatt C, Gajraj R, Hawker J, Neal K, Tahir M, Lawrence M, Gray SJ, Lucidarme J, Carr AD, Clark SA, et al. Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013. Euro Surveill 2014; 19:pii:20949; PMID:25394258
   PubMedGoogle Scholar
• Acheson P, Barron R, Borrow R, Gray S, Marodi C, Ramsay M, Waller J, Flood T. A cluster of four cases of meningococcal disease in a single nuclear family. Arch Dis Child 2012; 97:248-249; PMID:22247241; http://dx.doi.org/10.1136/archdischild-2011-301074
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-2210; PMID:17604802; http://dx.doi.org/10.1016/S0140-6736(07)61016-2
   PubMed Web of Science ®Google Scholar
• Dastouri F, Hosseini AM, Haworth E, Khandaker G, Rashid H, Booy R. Complications of serogroup B meningococcal disease in survivors: a review. Infect Disord Drug Targets 2015; 14:205-212; http://dx.doi.org/10.2174/1871526515999150320155614
   Google Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012; 11:774-783; PMID:22863608; http://dx.doi.org/10.1016/S1474-4422(12)70180-1
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-357.
   PubMed Web of Science ®Google Scholar
• Kelly RE, Jr., Shamberger RC, Mellins RB, Mitchell KK, Lawson ML, Oldham K, Azizkhan RG, Hebra AV, Nuss D, Goretsky MJ, et al. Prospective multicenter study of surgical correction of pectus excavatum: design, perioperative complications, pain, and baseline pulmonary function facilitated by internet-based data collection. J Am Coll Surg 2007; 205:205-216; PMID:17660066; http://dx.doi.org/10.1016/j.jamcollsurg.2007.03.027
   PubMed Web of Science ®Google Scholar
• Lennon D, Reid S, Stewart J, Jackson C, Crengle S, Percival T. Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic. J Paediatr Child Health 2012; 48:193-201; PMID:21996021; http://dx.doi.org/10.1111/j.1440-1754.2010.01969.x
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-1527; PMID:10227322; http://dx.doi.org/10.1001/jama.281.16.1520
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Hoiby EA, Bryn K, Oster P, Costantino P, Taha MK, et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-2205; PMID:15755595; http://dx.doi.org/10.1016/j.vaccine.2005.01.058
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006; 13:486-491; PMID:16603616; http://dx.doi.org/10.1128/CVI.13.4.486-491.2006
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-1096; PMID:1682541; http://dx.doi.org/10.1016/0140-6736(91)91961-S
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother 2015; 11:5-13; PMID:25483509; http://dx.doi.org/10.4161/hv.34293
   PubMed Web of Science ®Google Scholar
• Green LR, Eiden J, Hao L, Jones T, Perez J, McNeil LK, Jansen KU, Anderson AS. Approach to the discovery, development, and evaluation of a novel neisseria meningitidis serogroup B vaccine. Methods Mol Biol 2016; 1403:445-469; PMID:27076147; http://dx.doi.org/10.1007/978-1-4939-3387-7_25
   PubMedGoogle Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-2100; PMID:15039331; http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379-389; PMID:19534597; http://dx.doi.org/10.1086/600141
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086-6093; PMID:20619376; http://dx.doi.org/10.1016/j.vaccine.2010.06.083
   PubMed Web of Science ®Google Scholar
• Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥ 10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608-612.
   PubMed Web of Science ®Google Scholar
• TRUMENBA (Meningococcal Group B Vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer Inc, Philadelphia, PA, 2014.
   Google Scholar
• Vaccines and Related Biologic Products Advisory Committee. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Briefing document for the Vaccines and Related Biologic Products Advisory Committee Meeting. April 7, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM248586.pdf. Accessed October 30, 2015.
   Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013; 11:17; PMID:24016339; http://dx.doi.org/10.1186/1478-7954-11-17
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222-2227; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-1326.
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-786; PMID:12965904
   PubMedGoogle Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 Suppl 1: S58-67; PMID:11587814; http://dx.doi.org/10.1016/S0264-410X(01)00299-7
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(suppl 2):B112-116; PMID:19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195-196; PMID:11213098; http://dx.doi.org/10.1016/S0140-6736(00)03594-7
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. Methods Mol Med 2001; 66:289-304; PMID:21336762
   PubMedGoogle Scholar
• World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines. Geneva, Switzerland: March 8–9, 1999. WHO/V&B/99/19.
   Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367-1384; PMID:4977283; http://dx.doi.org/10.1084/jem.129.6.1367
   PubMed Web of Science ®Google Scholar
• Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine 2012; 30 Suppl 2: B10-17; PMID:22607894; http://dx.doi.org/10.1016/j.vaccine.2011.12.060
   PubMed Web of Science ®Google Scholar
• Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine 2011; 30:29-34; PMID:22075087; http://dx.doi.org/10.1016/j.vaccine.2011.10.068
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Surrogates of protection. In: Frosch M, Maiden M, eds. Handbook of meningococcal disease. Weinheim: Wiley-VCH; 2006:323-351.
   Google Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983; 40:257-264; PMID:6403466
   PubMed Web of Science ®Google Scholar
• Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21:11-16; PMID:1703960; http://dx.doi.org/10.1002/eji.1830210103
   PubMed Web of Science ®Google Scholar
• Harris SL, Donald RGK, Hawkins JC, Tan C, O'Neill RE, McNeil LK, Perez J, Anderson AS, Jansen KU, Jones TR. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J 2016; In press.
   Google Scholar
• Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013; 31:1569-1575; PMID:23352429; http://dx.doi.org/10.1016/j.vaccine.2013.01.021
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013; 32:364-371; PMID:23114369; http://dx.doi.org/10.1097/INF.0b013e31827b0d24
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces-Sanchez M, Martinon-Torres F, Beeslaar J, Szenborn L, Wysocki J, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597-607; PMID:22569484; http://dx.doi.org/10.1016/S1473-3099(12)70087-7
   PubMed Web of Science ®Google Scholar
• Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012; 30:6163-6174; PMID:22871351; http://dx.doi.org/10.1016/j.vaccine.2012.07.065
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc 2016; 5:180-187; PMID:26803328; http://dx.doi.org/10.1093/jpids/piv064
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J 2016; 35:548-554; PMID:26835974; http://dx.doi.org/10.1097/INF.0000000000001072
   PubMed Web of Science ®Google Scholar
• Reiner DM, Bhuyan P, Eiden JJ, Ginis J, Harris S, Jansen KU, Jiang Q, Jones TR, O'Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine 2016; 34:809-813; PMID:26707218; http://dx.doi.org/10.1016/j.vaccine.2015.12.016
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ostergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc 2016; 5:152-160; PMID:26407272; http://dx.doi.org/10.1093/jpids/piv039
   PubMed Web of Science ®Google Scholar
• Vesikari V, Senders S, Absalon J, Eiden JJ, Jansen KU, Beeslaar J, York LJ, Jones TR, Maansson R, Harris SL, et al. Phase 3 trial of the immunogenicity, safety, and lot consistency of bivalent rLP2086, a meningococcal serogroup B vaccine, in adolescents. Presented at: Pediatric Academic Societies Annual Meeting; April 30-May 3, 2016; Baltimore, MD, USA.
   Google Scholar
• Ostergaard L, Ward BJ, Beeslaar J, Eiden J, KU J, Absalon J, York L, Jones TR, Harris S, O'Neill RE, et al. Phase 3 trial of the immunogenicity and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, in young adults. Presented at: Pediatric Academic Societies Annual Meeting; April 30–May 3, 2016, Baltimore, MD, USA.
   Google Scholar
• Østergaard L, Ward BJ, Beeslaar JF, Eiden JJ, Jansen KU, Absalon J, York LJ, Jones TR, Harris SL, O'Neill R, et al. Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in young adults: bactericidal activity against a panel of antigenically diverse strains. Presented at: European Society for Paediatric Infectious Diseases Annual Meeting; May 10–14, 2016; Brighton, UK.
   Google Scholar
• Vesikari V, Senders S, Absalon J, Eiden JJ, Jansen KU, Beeslaar J, York LJ, Jones TR, Maansson R, Harris SL, et al. Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in adolescents: bactericidal activity against a panel of antigenically diverse strains. Presented at: European Society for Paediatric Infectious Diseases Annual Meeting; May 10–14, 2016; Brighton, UK.
   Google Scholar
• Tan C, Jansen KU, Anderson AS, Jones TR, Harris SL. Selection of ten additional diverse MnB SBA test strains to provide supportive immunogenicity data in Phase 3 trials of bivalent rLP2086. Presented at: International Pathogenic Neisseria Conference (IPNC); September 4–9, 2016; Manchester, UK.
   Google Scholar
• Atkinson B, Gandhi A, Balmer P. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy 2016; 36:880-892; PMID:27332671; http://dx.doi.org/10.1002/phar.1790
   PubMed Web of Science ®Google Scholar
• Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-1497; PMID:10227318; http://dx.doi.org/10.1001/jama.281.16.1493
   PubMed Web of Science ®Google Scholar
• Clark SA, Lekshmi A, Lucidarme J, Hao L, Tsao H, Lee-Jones L, Jansen KU, Newbold LS, Anderson AS, Borrow R. Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. J Infect 2016; 73:63-70; PMID:27025206; http://dx.doi.org/10.1016/j.jinf.2016.03.012
   PubMed Web of Science ®Google Scholar
• Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013; 32:1096-1101; PMID:23694830; http://dx.doi.org/10.1097/INF.0b013e31829aa63b
   PubMed Web of Science ®Google Scholar
• Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D. Meningococcal antigen typing system development and application to the evaluation of effectiveness of meningococcal B vaccine and possible use for other purposes. J Immunol Res 2015; 2015:353461; PMID:26351645; http://dx.doi.org/10.1155/2015/353461
   PubMed Web of Science ®Google Scholar
• Manigart O, Trotter C, Findlow H, Assefa A, Mihret W, Moti Demisse T, Yeshitela B, Osei I, Hodgson A, Quaye SL, et al. A seroepidemiological study of serogroup A meningococcal infection in the African meningitis belt. PLoS ONE 2016; 11:e0147928; PMID:26872255; http://dx.doi.org/10.1371/journal.pone.0147928
   PubMedGoogle Scholar
• Adis Insight (Springer). Meningococcal vaccine group B - GlaxoSmithKline. Available at: http://adisinsight.springer.com/drugs/800012858. Accessed March 10, 2016.
   Google Scholar
• Rossi R, Beernink PT, Giuntini S, Granoff DM. Susceptibility of meningococcal strains responsible for two serogroup B outbreaks on U.S. university campuses to serum bactericidal activity elicited by the MenB-4C vaccine. Clin Vaccine Immunol 2015; 22:1227-1234; PMID:26424832; http://dx.doi.org/10.1128/CVI.00474-15
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine 2015; 33:2629-2636; PMID:25882169; http://dx.doi.org/10.1016/j.vaccine.2015.04.015
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490-19495; PMID:20962280; http://dx.doi.org/10.1073/pnas.1013758107
   PubMed Web of Science ®Google Scholar
• Basta N, Mahmoud A, Wolfson J, Ploss A, Heller B, Hanna S, Johnsen P, Izzo R, Grenfell B, Findlow J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med 2016; 375:220-228; PMID:27468058; http://dx.doi.org/10.1056/NEJMoa1514866
   PubMed Web of Science ®Google Scholar
• McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417-3421; PMID:19200847; http://dx.doi.org/10.1016/j.vaccine.2009.01.075
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zlotnick GW, Camposano E, Logan SM, Novikova EG, Zhao XJ, Anderson AS, Pride MW, Jansen KU. Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis. Presented at: European Meningococcal Disease Society, 2011; Ljubljana, Slovenija.
   Google Scholar
• Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci U S A 2016; 113:2714-2719; PMID:26888286; http://dx.doi.org/10.1073/pnas.1521142113
   PubMed Web of Science ®Google Scholar
• Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, Sivonen A, Renkonen OV, Pettay O, Karanko V, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686-691; PMID:408682; http://dx.doi.org/10.1056/NEJM197709292971302
   PubMed Web of Science ®Google Scholar
• Sikkema DJ, Friedman KE, Corsaro B, Kimura A, Hildreth SW, Madore DV, Quataert SA. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines. Clin Diagn Lab Immunol 2000; 7:764-768; PMID:10973451
   PubMedGoogle Scholar
• King WJ, MacDonald NE, Wells G, Huang J, Allen U, Chan F, Ferris W, Diaz-Mitoma F, Ashton F. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J Pediatr 1996; 128:196-202; PMID:8636811; http://dx.doi.org/10.1016/S0022-3476(96)70389-X
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother 2016; 12:132-139; PMID:26575983; http://dx.doi.org/10.1080/21645515.2015.1058457
   PubMed Web of Science ®Google Scholar
• Gandhi A, Balmer P, York LJ. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R)). Postgrad Med 2016; 128:548-556; PMID:27467048; http://dx.doi.org/10.1080/00325481.2016.1203238
   PubMed Web of Science ®Google Scholar
• Taha M-K, Hawkins JC, Liberator PL, Deghmane A-E, Andrew L, Hao L, Jones TR, McNeil LK, O'Neill RE, Perez JL, et al. Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Submitted to Vaccine; 2016.
   Google Scholar